http://www.pvct.com Provectus Pharmaceuticals News Channel Mon, 20 Nov 2008 14:56:17 +0000 en http://www.pvct.com/images/pvct_logo_rss.gif http://www.pvct.com Thu, 20 Nov 2008 14:54:31 +0000 webmaster Professor John F. Thompson, MD presented an update on clinical testing of PV-10 for metastatic melanoma Wednesday, November 19th, at the Clinical Oncological Society of Australia 2008 Annual Scientific Meeting in Sydney, Australia. Professor Thompson noted that so far 39 of the planned 80 subjects have received at least one course of PV-10 treatment. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081120 Tue, 18 Nov 2008 14:19:33 +0000 webmaster The lead investigator for Provectus' Phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. http://www.pvct.com/pressrelease.html?article=20081118 Mon, 17 Nov 2008 13:54:12 +0000 webmaster has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. http://www.pvct.com/pressrelease.html?article=20081117 Tue, 4 Nov 2008 13:47:04 +0000 webmaster Provectus invited to present at the Rodman & Renshaw 10th Annual Healthcare Conference. http://www.pvct.com/pressrelease.html?article=20081104 Tue, 28 Oct 2008 13:52:34 +0000 webmaster Provectus announced today that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. http://www.pvct.com/pressrelease.html?article=20081028 Thu, 23 Oct 2008 15:40:33 +0000 webmaster In a Next Generation Pharmaceuticals article entitled "The Virtual Company", Provectus CFO Peter Culpepper discusses Provectus' business model with interviewer Willem van Leeuwen, Managing Director of QMR Technology B.V. http://www.ngpharma.com/currentissue/article.asp?art=275461&issue=285 Mon, 20 Oct 2008 14:01:47 +0000 webmaster Provectus' Chairman and CEO, Craig Dees, Ph.D., will be participating in several investment community events over the next two months. http://www.pvct.com/pressrelease.html?article=20081020 Fri, 17 Oct 2008 14:17:20 +0000 webmaster Provectus has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas, USA. Over the next several months, the Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States. http://www.pvct.com/pressrelease.html?article=20081017 Tue, 14 Oct 2008 17:10:03 +0000 webmaster The paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D., is available for purchase at the "Melanoma Research" website. http://www.melanomaresearch.com/pt/re/melres/paptoc.htm Tue, 14 Oct 2008 14:32:12 +0000 webmaster Provectus announced that "Melanoma Research" has published a paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D. The paper details results of Provectus' Phase 1 clinical trial of PV-10, and is scheduled for print publication in the December issue of the journal. http://www.pvct.com/pressrelease.html?article=20081014 Mon, 13 Oct 2008 12:30:21 +0000 webmaster Provectus CEO Craig Dees, Ph.D., is featured in an exclusive interview on WallSt.Net's 3-Minute Press Show. http://www.pvct.com/pressrelease.html?article=20081013 Mon, 6 Oct 2008 14:40:23 +0000 webmaster Provectus announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081006 Thu, 2 Oct 2008 15:31:11 +0000 webmaster Provectus announced that the lead investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, today presented clinical data on PV-10 at the "Perspectives in Melanoma XII" meeting at The Hague, The Netherlands. Professor Thompson's presentation was entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma." http://www.pvct.com/pressrelease.html?article=20081002 Mon, 29 Sep 2008 12:39:20 +0000 webmaster Provectus announced today that it has received approximately $1.1 million from the early conversion of some of its outstanding warrants. The Company now has approximately $5 million cash on hand to fund operations. http://www.pvct.com/pressrelease.html?article=20080929 Tue, 9 Sep 2008 13:32:07 +0000 webmaster Chairman and CEO, Craig Dees, Ph.D., will present at The Wall Street Analyst Forum 19th Annual Analyst Conference on Wednesday, September 10 at 11:50 a.m. Eastern time. http://www.pvct.com/pressrelease.html?article=20080909 Tue, 26 Aug 2008 14:21:47 +0000 webmaster Provectus announced today that the Lead Investigator for its phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Perspectives in Melanoma XII meeting at The Hague, The Netherlands. Professor Thompson's presentation, entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma", is scheduled for the afternoon symposium on emerging therapies scheduled for approximately 2:20 pm local time on Thursday October 2nd, 2008. http://www.pvct.com/pressrelease.html?article=20080826 Tue, 19 Aug 2008 14:09:17 +0000 webmaster The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story entitled "Melanoma breakthrough: a simple and less invasive cure" on the treatment of melanoma with PV-10. The story includes an interview with Professor John Thompson, as well as with a patient who was involved in the clinical study of PV-10 he is currently directing. http://www.pvct.com/inthenews.html?article=20080819&mode=0 Mon, 18 Aug 2008 18:20:33 +0000 webmaster A video of Prof. John Thompson's July 25th presentation at the Sydney Cancer Conference 2008 is available for viewing. A transcript of the presentation is also available. http://www.pvct.com/scc2008_video.html Mon, 23 Jul 2008 14:17:18 +0000 webmaster In an interview appearing on PM, a radio program broadcast on Radio National and ABC Local Radio in Australia, Professor John Thompson discusses his work with PV-10 for melanoma. http://www.abc.net.au/pm/content/2008/s2311345.htm Mon, 23 Jul 2008 13:35:18 +0000 webmaster An audio recording of the Business Update Conference Call held Tuesday, July 22, 2008 is available on the Provectus website. http://www.pvct.com/news/pvct-update-20080722.mp3